GlaxoSmithKline Inc
LONDON, UNITED KINGDOM - MAY 15: GlaxoSmithKline Chief Executive Andrew Witty poses with his medal after being honoured with a Knighthood by Prince Charles, Prince of Wales at an Investiture ceremony at Buckingham Palace on May 15, 2012 in London, England.
Connections
Quotes
My background is in building software for For- tune 500 companies, to help them predict hiring success. I worked with companies such as GlaxoSmithKline all across the U.S., Brazil, Russia ... But my true passion was in helping other entrepreneurs - and their biggest challenge [aside from cashflow] is hiring. Small businesses in North America spend $60-billion every year on job postings, recruiters, employee referral strategies and recruiting software - but hiring is still broken: turnover and retention haven't improved in more than 30 years.
In contrast, Novartis ('AA'/Stable), Sanofi ('AA-'/ Stable), GlaxoSmithKline ('A+'/Stable) and Bayer ('A-'/Stable) have less headroom within their current ratings to pursue debt-financed investments
GlaxoSmithKline (NYSE: GSK ) made an offer; we think it's too low; we'll look for higher offers and let you know when we have one.More quotes »
Newsday's coverage
-
GlaxoSmithKline in takeover bid for Human Genome
PLC has tabled an offer to take over U.S. drug maker Human Genome Sciences Inc. which values the target at nearly $2.6 billion.GlaxoSmithKline, which has profit-sharing agreements with HGS on three drugs but a minimal shareholding, said Wednesday it is offering Read more »
-
Report: James Murdoch to step down from BSkyB
extensive television businesses.He has also stepped down from the boards of auctioneer Sotheby's and prominent pharmaceutical firm GlaxoSmithKline PLC but remains deputy chief operating officer of News Corp.James Murdoch has repeatedly denied knowing about Read more »
Around the web
-
Exclusive: GSK eyes replacing Human Genome board: sources
YORK/LONDON (Reuters) - GlaxoSmithKline Plc plans to launch a campaign to replace the entire board of Human Genome Sciences Inc with its own nominees, stepping up its $2.6 billion hostile bid for the U.S. biotech company, sources familiar with the situation 10:23 AM from Reuters Mobile Read more »
-
Ligand Partner GlaxoSmithKline Submits US and European Regulatory Applications for use of PROMACTA/REVOLADE to Increase Platelet Counts in Patients with Hepatitis C
value; and future milestone and royalty payments. Actual events or results may differ from our expectations. There can be no assurance GlaxoSmithKline, or any of our other partners will continue clinical development of any compound(s); that clinical development 10:17 AM from Business Wire Read more »
-
GSK Announces Start of Phase III Programme for Combination of Dabrafenib (GSK2118436) and Trametinib (GSK1120212) in BRAF V600 Mutation-Positive Metastatic Cutaneous Melanoma
plc. today announced the start of a Phase III programme evaluating the combination of dabrafenib, its BRAF inhibitor, and trametinib, its MEK inhibitor, in patients with BRAF mutation-positive metastatic cutaneous melanoma. The studies comprising the programme 9:59 AM from Drugs.com Read more »
-
GlaxoSmithKline Confirms US District Court Ruling in Pronova Biopharma?s Favour on Lovaza Patents
plc (GSK) which has the marketing rights for Lovaza (omega-3-acid ethyl esters) in the US and Puerto Rico, confirmed that U.S. District Judge Sue Lewis Robinson, the presiding judge in the U.S. District Court for the District of Delaware, ruled in Pronova’s 9:58 AM from Drugs.com Read more »
-
Judge rules in GSK’s favor on patent
was printed from Triangle Business Journal Good news for British drug maker GlaxoSmithKline (NYSE: GSK): A U.S. District Court Judge has ruled in favor of the company’s patent claims regarding Lovaza. A drug aimed at lowering high triglycerides in blood, Lovaza’s 9:50 AM from Triangle Business Journal Read more »
